Details
- Cleveland Clinic, RIKEN and IBM were named finalists for the 2026 ACM Gordon Bell Prize for quantum-enabled simulation work spanning a 12,635-atom protein system.
- The collaboration combines IBM Quantum Heron processors with classical supercomputers, including Fugaku, Miyabi-G and RIKEN’s ROQUO GPU system, in a quantum-centric supercomputing workflow.
- The team’s approach used sample-based quantum diagonalization and embedded wavefunction methods to improve accuracy and reduce manual data-transfer steps.
- The underlying research was first published in May 2026, when the team reported the largest-known biologically meaningful molecule simulated with quantum hardware, followed by additional accuracy gains in September.
- The work reached up to 94 qubits and nearly 6,000 quantum operations in parts of the calculation, highlighting how hybrid quantum-classical methods are scaling for life-sciences workloads.
Impact
The result strengthens the case for quantum-centric supercomputing as a near-term research tool in drug discovery rather than a purely theoretical platform. If the workflow continues to improve, it could accelerate quantum software development, deepen HPC-quantum integration, and channel more funding toward hybrid chemistry and life-sciences pipelines over the next 12–24 months.
